Key result
Four-drug HFrEF therapy is linked to adverse events with a median onset of ~28 days.
Why the study?
The four-drug regimen for HFrEF reduces hospitalization and mortality risks, but key adverse drug events warranting attention remain to be identified.
What are the key adverse drug events and their time-to-onset associated with the four-drug regimen for HFrEF in a real-world setting?
Observational (n=1,237)
What are the key adverse drug events and their time-to-onset associated with the four-drug regimen for HFrEF in a real-world setting?
In patients receiving the four-drug regimen for HFrEF, early-onset acute kidney injury (median onset 28 days) is a frequent adverse event requiring particular focus alongside hypotension and hyperkalemia.
Answers are grounded in this paper and cite their sources.
Warrants early AKI vigilance with HFrEF four-drug therapy; hypothesis-generating from Level 5 data requiring prospective validation.
BACKGROUND: The four-drug regimen for heart failure with reduced ejection fraction (HFrEF) significantly reduces the risks of hospitalization and mortality. To identify key adverse drug events (ADEs) warranting attention with this regimen, we conducted a real-world pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) events. RESEARCH DESIGN AND METHODS: We collected ADE reports of the four-drug regimen from FAERS that matched this regimen over a 10-year period. Disproportionality analysis and subgroup analysis were performed using four algorithms. Time-to-onset (TTO) analysis was used to assess the temporal risk patterns of ADE occurrence. Lastly, logistic regression was applied to investigate the relationship-value between patient characteristics and ADEs. RESULTS: A total of 1,237 cases with 6,580 ADE reports were collected. Disproportionality analysis identified the most frequent ADEs as hypotension, acute kidney injury (AKI), and hyperkalemia. TTO analysis revealed a median TTO of 39 days for all important medical events, and the median TTO for AKI was 28 days, both fitting an early failure curve. CONCLUSION: In the comprehensive management of HFrEF with the four-drug regimen, in addition to routine monitoring of ADEs such as hypotension and hyperalemia, early-onset AKI should be a particular focus.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2025) conducted an observational in heart failure with reduced ejection fraction (HFrEF) (n=1,237). four-drug regimen for heart failure was evaluated on most frequent adverse drug events and time-to-onset. A four-drug regimen for HFrEF was frequently associated with adverse events including hypotension, hyperkalemia, and acute kidney injury, which had a median time-to-onset of 28 days.
Synapse has enriched 10 related papers. Consider them for comparative context: